In this issue:
- Cilta-cel vs. standard care in lenalidomide-refractory MM
- Induction VRd vs. KRd in newly diagnosed MM
- Isatuximab-carfilzomibdexamethasone for relapsed MM
- PFS associated with DRd and VRd
- BCMA CAR T-cell therapies in older patients with MM
- Pirtobrutinib in chronic lymphocytic leukaemia
- Obesity in AML not associated with inferior response/survival
- Pembrolizumab in relapsed/ refractory PMBCL
- Lymphoma in pregnancy
- Intensive chemotherapy ± gemtuzumab ozogamicin for NPM1-mutated AML
Please login below to download this issue (PDF)